446 related articles for article (PubMed ID: 10316797)
1. FDA-USP drug product problem reporting program--an update.
Wheatley LS
Hosp Formul; 1979 Mar; 14(3):359-60, 365. PubMed ID: 10316797
[No Abstract] [Full Text] [Related]
2. Drug Product Problem Reporting Program.
FDA Drug Bull; 1979 Aug; 9(3):18. PubMed ID: 467875
[No Abstract] [Full Text] [Related]
3. USP--promoting the public health.
Carothers N
Todays Surg Nurse; 1998; 20(1):35-9. PubMed ID: 9866636
[TBL] [Abstract][Full Text] [Related]
4. Reporting drug product defects--JCAHO.
Hoffmann RP
Hosp Pharm; 1989 Feb; 24(2):143-4. PubMed ID: 10318199
[No Abstract] [Full Text] [Related]
5. What you should know about FDA-USP Drug Product Problem Reporting Program.
McGinnis DM
Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
[No Abstract] [Full Text] [Related]
6. Drug information services at Eli Lilly and Company.
Pfeil-Doyle JL; Jones MD; Oberlin JA; Benitez J
Am J Hosp Pharm; 1990 Sep; 47(9):1996-8. PubMed ID: 2220850
[No Abstract] [Full Text] [Related]
7. FDA inspections of large volume and small volume parenteral manufacturers.
Shepherd RE
Bull Parenter Drug Assoc; 1976; 30(5):209-13. PubMed ID: 974306
[No Abstract] [Full Text] [Related]
8. Understanding the resources and organization of an industry-based drug information service.
Colvin CL
Am J Hosp Pharm; 1990 Sep; 47(9):1989-90. PubMed ID: 2220847
[No Abstract] [Full Text] [Related]
9. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
Marsh DA; Hoar ME
Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
[TBL] [Abstract][Full Text] [Related]
10. Reporting drug defects.
Belson JJ
Hosp Formul; 1975 Feb; 10(2):78-9. PubMed ID: 10316674
[No Abstract] [Full Text] [Related]
11. The intensified drug inspection program: procedures and results.
Clevenger WL
Bull Parenter Drug Assoc; 1969; 23(6):263-8. PubMed ID: 5355888
[No Abstract] [Full Text] [Related]
12. LyphoMed sparks worries.
Wagner M
Mod Healthc; 1988 Jul; 18(29):5. PubMed ID: 10325202
[No Abstract] [Full Text] [Related]
13. What's best for the patient?
Burkle WS
Am J Hosp Pharm; 1983 Apr; 40(4):558. PubMed ID: 6846359
[No Abstract] [Full Text] [Related]
14. The Food and Drug Administration drug registration and listing system.
Slavin M
Drug Inf J; 1975; 9(2-3):239-40. PubMed ID: 10236978
[No Abstract] [Full Text] [Related]
15. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
16. Biopharmaceutic equivalency and the role of the Food & Drug Administration.
Hodges RM
Am J Hosp Pharm; 1968 Mar; 25(3):121-7. PubMed ID: 5658859
[No Abstract] [Full Text] [Related]
17. Understanding the FDA's guarded system for classifying new drugs.
Schneiweiss F
Hosp Pharm; 1979 May; 14(5):262-4, 266, 268 passim. PubMed ID: 10316828
[No Abstract] [Full Text] [Related]
18. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
19. Drug safety: the viewpoint of the pharmaceutical manufacturing industry.
Wigle WW
Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099
[No Abstract] [Full Text] [Related]
20. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
